The statins: drug interactions of significance to the dental practitioner.
This report outlines the potential for concomitant use of dentally prescribed medication to increase the risk of statin-induced myopathy. The associated signs and symptoms of statin-induced myopathy are also highlighted, as well as the need for an accurate and updated drug history for all dental patients.


CONCLUSIONS
This article describes the recognized adverse interactions associated with concomitant drug therapy for patients on statins.
Stevenson
Helen
H
Liverpool University Dental Hospital.
Longman
Lesley P
LP
Randall
Christine
C
Field
E Anne
EA
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000935:Antifungal Agents / Q000009:adverse effects; D000069059:Atorvastatin; D001393:Azoles / Q000009:adverse effects; D032083:Citrus paradisi / Q000009:adverse effects; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D017742:Dental Care for Chronically Ill; D004347:Drug Interactions; D018565:Food-Drug Interactions; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D018942:Macrolides / Q000009:adverse effects; D017035:Pravastatin / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced; D019821:Simvastatin / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001393:Azoles; D065607:Cytochrome P-450 Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018942:Macrolides; D011758:Pyrroles; D003577:Cytochrome P-450 Enzyme System; D000069059:Atorvastatin; D019821:Simvastatin; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D017035:Pravastatin